ICB, such as PD-1 antibody, removes the inhibitory signal of effector T cells by blocking the binding of inhibitory receptor (such as PD-1) on the surface of T cells and inhibitory ligand (such as PD-L1) on the surface of tumor cells, enabling T cells to kill tumor cells [5]. Here, CD274 is linked to neoplasm.